一、 授权委托理财情况 1、 审议情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日第四届董事会第四次会议，审议通过《关于使用闲置自有资金购买理财产品的 议案》，公司计划使用不超过人民币 7,500 万元暂时闲置的自有资金购买安全性 高、流动性好的理财产品（包括但不限于结构性存款、收益凭证等），在上述额 度内资金可以循环滚动使用，自公司第四届董事会第四次会议审议通过之日起 12 个月内有效。 证券代码：920504 证券简称：博迅生物 公告编号：2026-001 上海博迅医疗生物仪器股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 公司董事会已对上海浦东发展银行股份有限公司虹口支行的基本情况、信用 情况及其交易履约能力等进行了必要的调查，本次理财不构成关联交易。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置自有资金购买理财产品的公告》（公告编号：2025-0 ...

Market Overview - The medical device sector experienced a decline of 0.74% on December 29, with Huakang Clean leading the drop [1] - The Shanghai Composite Index closed at 3965.28, up 0.04%, while the Shenzhen Component Index closed at 13537.1, down 0.49% [1] Top Performers - Meihao Medical (301363) saw a closing price of 25.04, with an increase of 8.30% and a trading volume of 197,100 shares, totaling a transaction value of 482 million yuan [1] - Mailande (688273) closed at 41.73, up 8.22%, with a trading volume of 55,200 shares and a transaction value of 227 million yuan [1] - Kangzhong Medical (688607) closed at 45.80, up 7.23%, with a trading volume of 40,200 shares and a transaction value of 180 million yuan [1] Underperformers - Huakang Clean (301235) closed at 39.21, down 8.54%, with a trading volume of 123,300 shares and a transaction value of 488 million yuan [2] - C Jianxin (688805) closed at 47.16, down 7.26%, with a trading volume of 89,000 shares and a transaction value of 426 million yuan [2] - Furuim Medical (300049) closed at 71.93, down 4.20%, with a trading volume of 66,800 shares and a transaction value of 485 million yuan [2] Capital Flow - The medical device sector saw a net outflow of 565 million yuan from institutional investors, while retail investors experienced a net inflow of 328 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Meihao Medical (301363) had a net outflow of 54.30 million yuan from institutional investors, with retail investors also showing a net outflow of 0.76 million yuan [3] - Jigaofazhan (600807) experienced a net inflow of 44.75 million yuan from institutional investors, while retail investors had a net outflow of 61.29 million yuan [3] - Kangzhong Medical (688626) saw a net inflow of 44.26 million yuan from institutional investors, with retail investors showing a slight net outflow [3]

关于取得 2 项发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、基本情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于近日取得国家 知识产权局颁发的 2 项《发明专利证书》，具体情况如下： （一）发明名称：一种培养设备及其防结露方法 专利号：ZL 2022 1 1394873.6 证券代码：920504 证券简称：博迅生物 公告编号：2025-118 上海博迅医疗生物仪器股份有限公司 专利权人：上海博迅医疗生物仪器股份有限公司 授权公告日：2025 年 12 月 2 日 授权公告号：CN 120872081 B 二、对公司的影响 专利申请日：2022 年 11 月 8 日 专利权人：上海博迅医疗生物仪器股份有限公司 授权公告日：2025 年 12 月 2 日 授权公告号：CN 115678766 B （二）发明名称：干燥含有可燃挥发物质的金属粉末的装置的控制系统 专利号：ZL 2025 1 1386605.3 专利申请日：2025 年 9 月 26 日 上述专利证书的取 ...

证券代码：920504 证券简称：博迅生物 公告编号：2025-117 上海博迅医疗生物仪器股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权现金管理情况 1. 审议情况 （一） 本次委托理财产品的基本情况 （二） 使用闲置募集资金进行现金管理的说明 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于 2025 年 3 月 6 日召开了第四届董事会第四次会议，审议通过了《关于使用闲置募集资金进行现 金管理的议案》，同意公司在确保不影响募集资金投资计划正常进行、保证募集 资金安全的前提下，公司拟使用额度不超过人民币 3,800 万元的闲置募集资金进 行现金管理，在上述额度和期限范围内资金可以循环滚动使用，自董事会审议通 过之日起 12 个月内有效，如单笔产品存续期超过前述有效期，则决议的有效期 自动顺延至该笔交易期满之日。 具体内容详见公司在北京证券交易所指定信息披露平台（www.bse.cn）上披 露的《关于使用闲置募集资金进行现金管 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [23] Core Insights - The market is experiencing low trading volumes and weak consolidation, with a focus on fundamental and mid-to-long-term logic [1] - On November 26, the North Exchange A-share trading volume reached 14.009 billion yuan, a decrease of 0.164 billion yuan from the previous trading day, with the North Exchange 50 Index closing at 1391.00, down 0.42% [2][9] - The report highlights a significant divergence in market hotspots, with high turnover thematic stocks and specialized innovative companies showing active performance [5] Summary by Sections Market Review - On November 26, 284 companies listed on the North Exchange saw 61 rise, 5 remain flat, and 218 decline [16] - The top five gainers were Zhu Laoliu (up 13.2%), Hongxi Technology (up 10.8%), Kaide Quartz (up 5.3%), Xin Ganjiang (up 5.2%), and Dapeng Industrial (up 4.1%) [16] - The top five decliners were Deer Chemical (down 7.3%), Rongyi Precision (down 6.5%), Boxun Biology (down 6.0%), *ST Yunchuang (down 5.8%), and Luqiao Information (down 5.5%) [16] Important News - Six departments issued a significant document aimed at enhancing the adaptability of supply and demand for consumer goods, targeting the formation of three trillion-level consumption fields and ten hundred-billion-level consumption hotspots by 2027 [3] - The "Infrastructure Classification" draft for comments is expected to accelerate the integration of vehicle-road-cloud systems into the standard system [19] Key Company Announcements - Vision Intelligence reported a reduction in shareholding by major shareholders, decreasing from 56.94% to 55.93% [20] - Jianbang Technology received a patent for a vehicle wiper assembly control system [21] - Boxun Biology obtained three patents for various AI and control systems [21]

证券代码：920504 证券简称：博迅生物 公告编号：2025-116 上海博迅医疗生物仪器股份有限公司 关于取得 3 项发明专利证书的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、基本情况 上海博迅医疗生物仪器股份有限公司（以下简称"公司"）于近日取得国家 知识产权局颁发的 3 项《发明专利证书》，具体情况如下： （一）发明名称：恒温恒湿箱及人工智能控制系统 专利号：ZL 2025 1 1259332.6 专利申请日：2025 年 9 月 4 日 （二）发明名称：基于深度强化学习的蒸汽灭菌器及智能控制系统 专利号：ZL 2025 1 1263335.7 专利申请日：2025 年 9 月 5 日 专利权人：上海博迅医疗生物仪器股份有限公司 授权公告日：2025 年 11 月 18 日 专利权人：上海博迅医疗生物仪器股份有限公司 授权公告日：2025 年 11 月 18 日 授权公告号：CN 120780080 B 上海博迅医疗生物仪器股份有限公司 董事会 2025 年 11 月 26 日 三 ...

Summary of Key Points Core Viewpoint - The trading volume on the Beijing Stock Exchange (BSE) reached 633 million shares with a total transaction value of 14.009 billion yuan, reflecting a decrease of 168 million yuan compared to the previous trading day. A total of 61 stocks closed higher, while 218 stocks closed lower [1]. Trading Performance - The stocks with the highest closing price increases included Zhu Laoliu (up 13.18%), Hongxi Technology (up 10.80%), and Kaide Quartz (up 5.27%) [1]. - The stocks with the largest declines were Deer Chemical (down 7.30%), Rongyi Precision (down 6.52%), and Boxun Biology (down 5.98%) [1]. Transaction Details - A total of 39 stocks had transaction values exceeding 100 million yuan, with the highest being Dapeng Industrial (588.12 million yuan), Tietuo Machinery (368.57 million yuan), and Better Ray (290.79 million yuan) [1]. - The trading activity showed that 14 stocks had a turnover rate exceeding 10%, with 4 stocks exceeding 20%. The highest turnover rates were for Dapeng Industrial (69.22%), Tietuo Machinery (29.98%), and Zhu Laoliu (21.64%) [1]. Stock Performance Table - A detailed table lists various stocks, their closing prices, percentage changes, turnover rates, and transaction values, highlighting the performance of individual stocks on the BSE [2][3][4][5][6][7][8][9][10].

证券代码：920504 证券简称：博迅生物 公告编号：2025-115 上海博迅医疗生物仪器股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权委托理财情况 2、 披露标准 根据《北京证券交易所股票上市规则》相关规定，交易的成交金额占上市公 司最近一期经审计净资产的 10%以上且超过 1,000 万元的应当予以披露；上市公 司连续 12 个月滚动发生理财的，以该期间最高余额为成交额，适用上述标准。 公司本次以闲置自有资金购买理财产品金额为人民币 2,000 万元，本次购买 理财后，公司使用闲置自有资金购买的理财产品未到期余额为 6,112.72 万元， 占公司最近一期经审计净资产的 31.56%。公司本次使用闲置自有资金购买理财 产品的金额达到披露标准，现予以披露。 二、 本次委托理财情况 | 受托方 | | | 产品金 | 预计年化 | 产品 | 收益 | 投资 | 资金 | | | --- | --- | --- | --- | --- ...

证券代码：920504 证券简称：博迅生物 公告编号：2025-114 上海博迅医疗生物仪器股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 授权现金管理情况 1. 审议情况 2. 披露标准 根据《北京证券交易所股票上市规则》相关规定，交易的成交金额占上市公 司最近一期经审计净资产的 10%以上且超过 1,000 万元的应当予以披露；上市公 司连续 12 个月滚动发生委托理财的，以该期间最高余额为成交额，适用上述标 准。 公司本次以闲置募集资金进行现金管理的金额合计 3,100 万元，全部用于购 买结构性存款。本次现金管理后，公司使用闲置募集资金进行现金管理未到期余 额为 3,100 万元，占公司最近一期经审计净资产的 16.01%。根据《北京证券交 易所股票上市规则》的相关规定，公司本次使用闲置募集资金进行现金管理的金 额达到披露标准，现予以披露。 二、 本次委托理财情况 | 受托方 | | 产品类 | 产品名称 | | 产品金 额（万 | ...

Core Viewpoint - Shanghai Boxun Medical Biological Instrument Co., Ltd. has released its Q3 2025 financial report, showing stable growth in revenue and net profit, while also highlighting significant changes in cash flow and asset management [3]. Financial Data Summary Key Financial Metrics - Total assets increased to CNY 255.04 million, up 1.27% from the previous year [5]. - Net assets attributable to shareholders rose to CNY 200.04 million, reflecting a 3.29% increase [5]. - The asset-liability ratio decreased to 20.70% for the parent company and 21.57% for the consolidated entity [5]. Revenue and Profitability - Year-to-date revenue reached CNY 84.58 million, a slight increase of 0.43% compared to the same period last year [5]. - Net profit attributable to shareholders was CNY 8.54 million, up 4.50% year-on-year [5]. - Basic earnings per share improved to CNY 0.20, a 5.26% increase [5]. Quarterly Performance - Q3 2025 revenue was CNY 32.06 million, representing a 12.81% increase from Q3 2024 [5]. - Net profit for Q3 2025 was CNY 4.91 million, up 14.39% year-on-year [5]. - Cash flow from operating activities showed a significant improvement, with a net outflow of CNY 3.52 million, a 54.78% reduction in outflow compared to the previous year [5]. Significant Changes in Financial Data Cash Management - Cash and cash equivalents decreased by 44.89% to CNY 42.13 million, primarily due to the use of idle funds for cash management [7]. - Accounts receivable increased by 581.24% to CNY 24.05 million, attributed to the timing of payments from distributors [7]. Other Financial Changes - Other current assets increased by 469.79% to CNY 20.60 million, reflecting investments in short-term bank deposits [7]. - Deferred income rose by 54.89% to CNY 1.89 million, due to government subsidies received for R&D projects [8]. Shareholder Structure - The total number of shares outstanding remained at 43.33 million, with major shareholders holding significant stakes [11]. - The largest shareholder, Lv Mingjie, holds 60.33% of the shares, with no changes in ownership during the reporting period [11]. Related Party Transactions - The company engaged in minor related party transactions, including sales to affiliated entities, which did not require board approval due to their small scale [16][17].